ExpreS2ion Biotech Holding AB (publ) (STO: EXPRS2)
Sweden
· Delayed Price · Currency is SEK 20.80
-1.20 (-5.45%)
Dec 27, 2024, 5:29 PM CET
STO: EXPRS2 Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Operating Revenue | 3.52 | 7.05 | 5.09 | 12.23 | 5.26 | 11.69 | Upgrade
|
| Other Revenue | 4.41 | 1.75 | 1.06 | 1.5 | 10 | 2.14 | Upgrade
|
| Revenue | 7.93 | 8.8 | 6.15 | 13.73 | 15.26 | 13.83 | Upgrade
|
| Revenue Growth (YoY) | -2.06% | 43.07% | -55.21% | -10.04% | 10.37% | 55.94% | Upgrade
|
| Cost of Revenue | 4.07 | 3.65 | 5.08 | 7.51 | 6.1 | 3.4 | Upgrade
|
| Gross Profit | 3.86 | 5.15 | 1.07 | 6.22 | 9.16 | 10.43 | Upgrade
|
| Selling, General & Admin | 41.7 | 58.1 | 56.14 | 35.89 | 37.22 | 24.4 | Upgrade
|
| Research & Development | 29.1 | 51.42 | 71.32 | 9.82 | 0.22 | - | Upgrade
|
| Operating Expenses | 72.45 | 111.12 | 128.68 | 47.51 | 40.36 | 27.28 | Upgrade
|
| Operating Income | -68.59 | -105.97 | -127.61 | -41.3 | -31.2 | -16.85 | Upgrade
|
| Interest Expense | -0.78 | -0.5 | -0.87 | - | -3.53 | -0.97 | Upgrade
|
| Interest & Investment Income | 2.75 | 1.91 | 1.9 | - | - | 0 | Upgrade
|
| Earnings From Equity Investments | 26.69 | 4.59 | - | 0.67 | -0.19 | -1.82 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | 0.21 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -39.94 | -99.97 | -126.58 | -40.42 | -34.92 | -19.64 | Upgrade
|
| Other Unusual Items | - | - | - | -7.1 | - | - | Upgrade
|
| Pretax Income | -39.94 | -99.97 | -126.58 | -47.52 | -34.92 | -19.64 | Upgrade
|
| Income Tax Expense | -5.93 | -8.57 | -7.98 | -3.59 | -3.21 | -2.38 | Upgrade
|
| Net Income | -34.01 | -91.4 | -118.61 | -43.93 | -31.71 | -17.26 | Upgrade
|
| Net Income to Common | -34.01 | -91.4 | -118.61 | -43.93 | -31.71 | -17.26 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 36.62% | 31.49% | 20.02% | 68.61% | 31.37% | 14.39% | Upgrade
|
| EPS (Basic) | -23.33 | -79.22 | -135.18 | -60.09 | -73.14 | -52.29 | Upgrade
|
| EPS (Diluted) | -23.33 | -79.22 | -135.18 | -60.09 | -73.14 | -52.29 | Upgrade
|
| Free Cash Flow | -44.3 | -102.9 | -100 | -46.36 | -19.06 | -11.5 | Upgrade
|
| Free Cash Flow Per Share | -30.39 | -89.19 | -113.97 | -63.42 | -43.96 | -34.84 | Upgrade
|
| Gross Margin | 48.66% | 58.55% | 17.38% | 45.28% | 60.02% | 75.42% | Upgrade
|
| Operating Margin | -864.86% | -1204.28% | -2074.89% | -300.78% | -204.39% | -121.84% | Upgrade
|
| Profit Margin | -428.76% | -1038.77% | -1928.54% | -319.92% | -207.78% | -124.79% | Upgrade
|
| Free Cash Flow Margin | -558.53% | -1169.47% | -1625.97% | -337.66% | -124.88% | -83.15% | Upgrade
|
| EBITDA | -66.94 | -104.36 | -126.35 | -39.8 | -28.28 | -13.97 | Upgrade
|
| EBITDA Margin | - | - | - | -289.87% | -185.28% | -101.04% | Upgrade
|
| D&A For EBITDA | 1.65 | 1.6 | 1.25 | 1.5 | 2.92 | 2.88 | Upgrade
|
| EBIT | -68.59 | -105.97 | -127.61 | -41.3 | -31.2 | -16.85 | Upgrade
|
| EBIT Margin | - | - | - | - | -204.39% | -121.84% | Upgrade
|
| Revenue as Reported | 7.93 | 8.8 | 6.15 | 13.73 | 15.26 | 13.83 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.